- Home
- GRFS
GRFS
Grifols S.A.
as 11-15-2024 3:35pm EST
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
| Founded: | 1940 | Country: | Spain |
| Employees: | N/A | City: | N/A |
| Market Cap: | 6.0B | IPO Year: | 2006 |
| Target Price: | $10.50 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Sell | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.30 - $12.15 | Next Earning Date: | 01-01-0001 |
| Revenue: | $7,814,096,584 | Revenue Growth: | 7.21% |
| Revenue Growth (this year): | 8.86% | Revenue Growth (next year): | 7.00% |
Latest Grifols S.A. News
GRFS Breaking Stock News: Dive into GRFS Ticker-Specific Updates for Smart Investing
Bloomberg
3 days ago
Banks to Pitch Roughly €11 Billion Buyout Debt for Grifols
GuruFocus.com
9 days ago
Grifols SA (GIFLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Cash ...
Morningstar Research
9 days ago
Analyst Report: Grifols, S.A.
MT Newswires
12 days ago
Market Chatter: Brookfield Asset Management Seeks Details of Grifols Related-Party Deals
Bloomberg
12 days ago
Brookfield Seeks More Information on Grifols Related-Party Deals
Simply Wall St.
17 days ago
High Growth Tech Stocks to Watch in November 2024
Simply Wall St.
18 days ago
Grifols And 2 Other Stocks That Might Be Trading Below Estimated Value
TipRanks
18 days ago
Grifols receives FDA approval to treat surgical bleeding with FS solution
Compare GRFS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GRFS Grifols S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.